-
Eur Radiol: Feasibility study of MRI-guided breast biopsy based on diffusion-weighted imaging
Time of Update: 2021-03-19
We identified 64 of 87 operations that can detect lesions in DWI; added DWI sequences to the standard protocol to locate lesions and biopsy devices, and evaluate the correct location of site markers.
-
Bleeding gums is not a small problem!
Time of Update: 2021-03-19
However, when the liver is affected by diseases such as hepatitis, cirrhosis or cancer, its function will be reduced, and the bacteria can survive longer, so it may cause more damage.
Secondly, reactive oxygen metabolites may be the physiopathological link between periodontitis and liver cancer.
-
China NMPA accepts application for clinical trial of PD-1/TGF-β bifunctional fusion protein
Time of Update: 2021-03-19
(Junshi Biosciences) announced that its clinical trial application PD-1 / TGF-β bifunctional fusion protein injection JS201 (JS201) has been China's State Drug Administration accepted Bureau (NMPA).
Its anti-PCSK9 monoclonal antibody is the first clinical trial approved by NMPA in China.
-
Ilixadencel treatment of kidney cancer, the patient's survival period can be significantly prolonged
Time of Update: 2021-03-19
Biopharmaceutical company Immunicum today announced that in the updated data of the phase II MERECA randomized trial, ilixadencel combined with sunitinib has achieved positive results in the first-line treatment of patients with metastatic renal cell carcinoma (mRCC).
-
AstraZeneca withdraws Imfinzi's advanced bladder cancer indication in the U.S.
Time of Update: 2021-03-19
For patients with tumor cells and/or tumor infiltrating immune cells with high expression (≥25%) PD-L1, compared with standard treatment, Imfinzi monotherapy did not achieve the primary endpoint of improving overall survival (OS).
-
Why does Junshi PD-1 cooperate with AstraZeneca?
Time of Update: 2021-03-19
According to the press release, Junshi Biologics has the exclusive right to promote all the approved indications (melanoma and nasopharyngeal carcinoma) of teriprizumab in non-core markets in China, as well as urinary system tumors (urinary tract tumors) that will be approved for marketing in the future.
-
Br J Cancer: HPV-positive oropharyngeal squamous cell carcinoma changes to the gut microbiome after radiotherapy and chemotherapy
Time of Update: 2021-03-19
In this study, the researchers analyzed the oral and intestinal microbiome in the cohort of HPV+OPSCC patients and evaluated the impact of radiotherapy and chemotherapy (CRT).
-
Eur Radiol: How to evaluate the efficacy of sorafenib for advanced liver cancer?
Time of Update: 2021-03-19
An independent predictor of progressive survival (PFS), and verified that LS can predict the occurrence of significant liver injury (grade ≥3) after sorafenib administration, providing a new reference for the clinical development of personalized treatment plans for patients with advanced HCC in accordance with.
-
Eur Radiol: The influence of CT slice thickness in radiomics model in predicting survival rate of non-small cell lung cancer
Time of Update: 2021-03-19
Table 2 In the validation set, three radioomics models with different layer thicknesses are used to predict the performance of DFS.
CT layer thickness has no significant impact on the performance of the radiomic model for predicting DFS in patients with non-small cell lung cancer.
-
The second domestic third-generation EGFR-TKI was approved for listing
Time of Update: 2021-03-19
At the same time, the drug is targeted at EGFR exon 19 deletion or extracellular The Phase III clinical trial for the treatment (first-line treatment) of adult patients with locally advanced or metastatic non-small cell lung cancer with a substitution mutation of Exon 21 (L858R) was launched in June 2019, and it is expected to submit a marketing application in 2022.
-
J Clin Oncol: Phase 3 trial results of Andecaliximab combined with mFOLFOX6 as a first-line therapy for advanced gastric/gastroesophageal junction adenocarcinoma
Time of Update: 2021-03-19
This study is a randomized, double-blind, placebo (PBO)-controlled multicenter Phase III study, which aims to evaluate mFOLFOX6 with or without ADX in the treatment of untreated human epidermal growth factor receptor 2 negative gastric cancer or GEJ glands Efficacy and safety of cancer.
-
Merck autonomously withdraws Keytruda in the U.S. for indications for metastatic small cell lung cancer
Time of Update: 2021-03-19
On March 1, Merck announced the voluntary withdrawal of Keytruda (pembrolizumab) in the United States for the treatment of patients with metastatic small cell lung cancer (SCLC) who have undergone platinum-based chemotherapy and at least one other treatment regimen or after the disease has progressed.
-
Plos Med: Breast cancer patients are at higher risk of anxiety and depression!
Time of Update: 2021-03-19
Recently, a study published in the journal Plos Med showed that compared with women without cancer, breast cancer survivors have a higher risk of anxiety, depression, sleep, sexual dysfunction, fatigue, and pain.
-
Nat Commun: CD318, TSPAN8 and CD66c are candidate targets for CAR-T cell therapy for pancreatic cancer
Time of Update: 2021-03-19
Among the CAR-T cells specific for CD66c, CD318, and TSPAN8, CD318 has shown the efficacy of stabilizing the disease to completely eradicating tumors, followed by TSPAN8, which is the most promising potential based on functionality and predicted safety Candidate targets.
1038/s41467-021-21774-4">Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma .
-
NEJM: In 70 years of ups and downs, the status of albumin infusion in the treatment of liver cirrhosis will be rewritten!
Time of Update: 2021-03-19
For patients hospitalized with decompensated liver cirrhosis, infusion of albumin to increase the albumin level to the goal of ≥30g/L is not more beneficial than the current standard care.
-
Is a blessing or a curse?
Time of Update: 2021-03-19
This led AstraZeneca to withdraw Imfinzi's eligibility to market for bladder cancer indications in the United States, and patients who previously used Imfinzi must consult a doctor before proceeding to the next treatment.
-
Ten months after the introduction of anti-tumor products was approved for marketing, the cooperation was terminated for US$20 million
Time of Update: 2021-03-19
Previous public reports showed that as early as August 2018, Beihai Kangcheng signed an exclusive license agreement with Puma Bio for the development and commercialization of neratinib in mainland China, Taiwan, Hong Kong and Macau.
-
Nat Commun: A clinical study of neoadjuvant anti-OX40 therapy (MEDI6469) in the treatment of patients with head and neck squamous cell carcinoma
Time of Update: 2021-03-19
Analysis of survival rate of patients after neoadjuvant anti-OX40 treatmentAll in all, the results of the study show that anti-OX40 therapy is safe before surgery and can increase the activity and proliferation of CD4+ and CD8+ T cells in blood and tumors.
-
AACR 2021: NX-1607 in the treatment of colorectal cancer and triple-negative breast cancer, the preclinical research results are significant
Time of Update: 2021-03-19
It has shown significant anti-tumor efficacy in animal models of colorectal cancer and triple-negative breast cancer .
Lymphoma, Colorectal Cancer, Breast Cancer +The E3 ubiquitin ligase CBL-B is expressed in T cells, where it plays an important role as a negative regulator of immune activation.
-
226 million R&D costs have been lost, Biotech terminates an ADC project under development
Time of Update: 2021-03-19
At the same time, Biotech stated that according to the Frost & Sullivan report, the total market size of anti-HER2 ADC drugs for HER2-positive breast cancer in China is expected to be approximately 17 million yuan in 2020, and is expected to grow at a compound annual growth rate of 207.
